Saroglitazar, a Dual PPAR α/γ Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis

医学 内科学 甘油三酯 糖尿病 非酒精性脂肪肝 内分泌学 胃肠病学 安慰剂 脂蛋白 胆固醇 脂肪肝 疾病 替代医学 病理
作者
Mohammad Shadab Siddiqui,Deven Parmar,Farheen Sheikh,Shiv Kumar Sarin,Laura M. Cisneros,Samer Gawrieh,Taufik Momin,Ajay Duseja,Arun J. Sanyal
出处
期刊:Clinical Gastroenterology and Hepatology [Elsevier BV]
卷期号:21 (10): 2597-2605.e2 被引量:25
标识
DOI:10.1016/j.cgh.2023.01.018
摘要

Background & Aims Cardiovascular disease is the leading cause of mortality in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate the effects of saroglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, on serum lipids in patients with NAFLD. Methods A total of 221 patients (saroglitazar, 130; placebo, 91) with NAFLD from phase 2 and 3 double-blinded placebo-controlled randomized clinical trials were pooled to assess the impact of saroglitazar magnesium 4 mg on traditional lipids, very low density lipoprotein cholesterol (VLDL-C), and small dense LDL-C (sdLDL-C). Change from baseline in lipid parameters was performed by using analysis of covariance including treatment as fixed effect and baseline value, diabetes, hypertension, and statin use as covariates. Results Treatment with saroglitazar significantly improved total cholesterol (–17 mg/dL, 95% confidence interval [CI], –24 to 9; P < .001), triglyceride (–45 mg/dL, 95% CI, –60 to 31; P < .001), low-density lipoprotein cholesterol (–8 mg/dL, 95% CI, –15 to –1; P = .01), and VLDL-C (–8 mg/dL, –14 to –3; P < .001). Saroglitazar improved serum lipids as early as 4–6 weeks of initiation of therapy, and these effects persisted for duration of therapy. Saroglitazar also improved the highly atherogenic sdLDL-C (–10 mg/dL, –17 to –2; P = .01). In subgroup analysis of patients with either diabetes or hypertension, saroglitazar significantly improved serum lipids. Conclusions Saroglitazar improved the serum atherogenic lipoprotein profile in patients with NAFLD, irrespective of comorbid conditions and statin use. Saroglitazar has the potential to not only positively affect liver disease but also reduce cardiovascular risk in patients with NAFLD. (Trials registrations: CTRI 2015/10/006236, CTRI 173300410A0106, NCT03863574, and NCT03061721) Cardiovascular disease is the leading cause of mortality in nonalcoholic fatty liver disease (NAFLD). The aim of this study was to evaluate the effects of saroglitazar, a dual peroxisome proliferator-activated receptor α/γ agonist, on serum lipids in patients with NAFLD. A total of 221 patients (saroglitazar, 130; placebo, 91) with NAFLD from phase 2 and 3 double-blinded placebo-controlled randomized clinical trials were pooled to assess the impact of saroglitazar magnesium 4 mg on traditional lipids, very low density lipoprotein cholesterol (VLDL-C), and small dense LDL-C (sdLDL-C). Change from baseline in lipid parameters was performed by using analysis of covariance including treatment as fixed effect and baseline value, diabetes, hypertension, and statin use as covariates. Treatment with saroglitazar significantly improved total cholesterol (–17 mg/dL, 95% confidence interval [CI], –24 to 9; P < .001), triglyceride (–45 mg/dL, 95% CI, –60 to 31; P < .001), low-density lipoprotein cholesterol (–8 mg/dL, 95% CI, –15 to –1; P = .01), and VLDL-C (–8 mg/dL, –14 to –3; P < .001). Saroglitazar improved serum lipids as early as 4–6 weeks of initiation of therapy, and these effects persisted for duration of therapy. Saroglitazar also improved the highly atherogenic sdLDL-C (–10 mg/dL, –17 to –2; P = .01). In subgroup analysis of patients with either diabetes or hypertension, saroglitazar significantly improved serum lipids. Saroglitazar improved the serum atherogenic lipoprotein profile in patients with NAFLD, irrespective of comorbid conditions and statin use. Saroglitazar has the potential to not only positively affect liver disease but also reduce cardiovascular risk in patients with NAFLD. (Trials registrations: CTRI 2015/10/006236, CTRI 173300410A0106, NCT03863574, and NCT03061721)
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
之_ZH完成签到 ,获得积分10
8秒前
gds2021完成签到 ,获得积分10
10秒前
你好呀嘻嘻完成签到 ,获得积分10
10秒前
梅特卡夫完成签到,获得积分10
12秒前
熊雅完成签到,获得积分10
13秒前
15秒前
睡到自然醒完成签到 ,获得积分10
16秒前
cis2014完成签到,获得积分10
18秒前
独特的大有完成签到 ,获得积分10
18秒前
量子星尘发布了新的文献求助10
19秒前
21秒前
xingyi完成签到,获得积分10
23秒前
24秒前
舒心的秋荷完成签到 ,获得积分10
27秒前
zz123发布了新的文献求助10
28秒前
liaomr完成签到 ,获得积分10
28秒前
粗犷的灵松完成签到,获得积分10
29秒前
吃小孩的妖怪完成签到 ,获得积分10
29秒前
ncuwzq完成签到,获得积分10
31秒前
yshj完成签到 ,获得积分10
32秒前
34秒前
净禅完成签到 ,获得积分10
36秒前
38秒前
迷人的寒风完成签到,获得积分10
39秒前
39秒前
water应助科研通管家采纳,获得10
40秒前
Lucas应助HHHAN采纳,获得10
42秒前
无情修杰完成签到 ,获得积分10
43秒前
小柒完成签到 ,获得积分10
45秒前
聪慧芷巧发布了新的文献求助10
46秒前
47秒前
51秒前
蓝意完成签到,获得积分0
52秒前
xiaohongmao完成签到,获得积分10
57秒前
1分钟前
qweerrtt完成签到,获得积分10
1分钟前
1分钟前
与共发布了新的文献求助10
1分钟前
carly完成签到 ,获得积分10
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038066
求助须知:如何正确求助?哪些是违规求助? 3575779
关于积分的说明 11373801
捐赠科研通 3305584
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022